Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma

被引:9
|
作者
Yamashita, Suguru [1 ]
Overman, Michael J. [2 ]
Wang, Huamin [3 ]
Zhao, Jun [3 ]
Okuno, Masayuki [1 ]
Goumard, Claire [1 ]
Tzeng, Ching-Wei [1 ]
Kim, Michael [1 ]
Fleming, Jason B. [1 ]
Vauthey, Jean-Nicolas [1 ]
Katz, Matthew H. [1 ]
Lee, Jeffrey E. [1 ]
Conrad, Claudius [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
PANCREATIC DUCTAL ADENOCARCINOMA; COLORECTAL LIVER METASTASES; PHASE-II; FRACTIONATED CHEMORADIATION; NEOADJUVANT CHEMORADIATION; TRACT CANCER; VATER; CHEMOTHERAPY; GEMCITABINE; CARCINOMA;
D O I
10.1245/s10434-017-6098-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The prognostic impact of pathologic response to preoperative therapy on patients with duodenal adenocarcinoma (DA) and ampullary adenocarcinoma (AMPA) has not been established. Methods. A retrospective review of 266 patients who underwent curative resection for DA (n = 97) or AMPA (n = 169) during 1993-2015 was performed. For patients who underwent preoperative therapy, the pathologic response was systematically evaluated and classified as major (0-49% of viable residual tumor cells) or minor (>= 50% of viable residual tumor cells). Uni- and multivariable analyses were performed to identify predictors of pathologic response and disease-specific survival (DSS). Results. For the 79 patients treated with preoperative therapy (DA: n = 34; AMPA: n = 45), concomitant use of radiation (80%, 67/79) was the sole independent predictor of major pathologic response (odds ratio [OR] 8.17; 95% confidence interval [CI] 1.85-58.2; P = 0.005). The patients with major pathologic response had a better 5-year DSS rate than the patients with minor pathologic response (DA: 65 vs 25%; P = 0.028; AMPA: 85 vs 43%; P = 0.016). In the multivariable analysis of DSS for the 79 patients who underwent preoperative therapy, major pathologic response was the sole predictor of improved DSS (hazard ratio [HR] 2.88; 95% CI 1.41-5.98; P = 0.004). In the multivariable analysis of DSS for the entire cohort, pathologic stage 2 or lower was the sole predictor of better DSS. Conclusion. The major pathologic response to preoperative therapy predicted improved DSS after resection of DA and AMPA and might represent a new prognosticator after resection of DA and AMPA.
引用
收藏
页码:3954 / 3963
页数:10
相关论文
共 50 条
  • [31] Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma
    Miyoshi, Tomohiro
    Aokage, Keiju
    Katsumata, Shinya
    Tane, Kenta
    Ishii, Genichiro
    Tsuboi, Masahiro
    ANNALS OF THORACIC SURGERY, 2019, 108 (01): : 249 - 255
  • [32] The utility of immunohistochemistry aids diagnosis of colonization of duodenal mucosa by invasive ampullary adenocarcinoma
    Obeng, Rebecca
    Pehlivanoglu, Burcin
    Schneider, Frank
    Tracht, Jessica
    Krasinskas, Alyssa
    Reid, Michelle
    Xue, Yue
    MODERN PATHOLOGY, 2019, 32
  • [33] The utility of immunohistochemistry aids diagnosis of colonization of duodenal mucosa by invasive ampullary adenocarcinoma
    Obeng, Rebecca
    Pehlivanoglu, Burcin
    Schneider, Frank
    Tracht, Jessica
    Krasinskas, Alyssa
    Reid, Michelle
    Xue, Yue
    LABORATORY INVESTIGATION, 2019, 99
  • [34] Carbonic Anhydrases II and IX in Non-ampullary Duodenal Adenomas and Adenocarcinoma
    Nortunen, Minna
    Parkkila, Seppo
    Saarnio, Juha
    Huhta, Heikki
    Karttunen, Tuomo J.
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2021, 69 (11) : 677 - 690
  • [35] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response
    Ajani, Jaffer A.
    Winter, Kathryn
    Okawara, Gordon S.
    Donohue, John H.
    Pisters, Peter W. T.
    Crane, Christopher H.
    Greskovich, John F.
    Anne, P. Rani
    Bradley, Jeffrey D.
    Willett, Christopher
    Rich, Tyvin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3953 - 3958
  • [36] Clinical Significance of Acellular Mucin in Rectal Adenocarcinoma Patients With a Pathologic Complete Response to Preoperative Chemoradiation
    Smith, Kerrington D.
    Tan, Dongfeng
    Das, Prajnan
    Chang, George J.
    Kattepogu, Kiran
    Feig, Barry W.
    Skibber, John M.
    Rodriguez-Bigas, Miguel A.
    ANNALS OF SURGERY, 2010, 251 (02) : 261 - 264
  • [37] Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report
    Tang, Yong
    Li, Yadan
    Zhang, Lei
    Tong, Guihui
    Ou, Zhu'an
    Wang, Zhuocai
    Zhang, Henghui
    Qiao, Guibin
    THORACIC CANCER, 2020, 11 (04) : 1094 - 1098
  • [38] Adjuvant therapy for ampullary adenocarcinoma: The Johns Hopkins experience
    Zhou, J.
    Hsu, C.
    Winter, J.
    Pawlik, T. M.
    Laheru, D.
    Akbar, U.
    Swartz, M.
    Schulick, R.
    Cameron, J.
    Herman, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S243 - S244
  • [39] Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means?
    Mansour, John C.
    Schwarz, Roderich E.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (06) : 1465 - 1479
  • [40] Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy
    Alexander P. Stark
    Naruhiko Ikoma
    Yi-Ju Chiang
    Jeannelyn S. Estrella
    Prajnan Das
    Bruce D. Minsky
    Mariela M. Blum
    Jaffer A. Ajani
    Paul Mansfield
    Brian D. Badgwell
    Annals of Surgical Oncology, 2019, 26 : 3602 - 3610